Boston startup Gelesis has picked up $12 million in venture funding, cash that'll support its novel approach to obesity treatment: a pill that disperses expanding particles in the gut to make patients feel full.
Cambridge, U.K.'s Kymab touts its drug development platform as an ideal way to spotlight new antibodies, and some bright minds would seem to agree, as the Wellcome Trust and Bill and Melinda Gates Foundation have teamed up on a $40 million round for the biotech.
With $45 million in venture commitments under its belt, Proteon is set to roll into a late-stage study for its top candidate, with no need for Big Pharma help.
ZS Pharma is executing a familiar biotech gambit. The Texas-based biotech raised $55 million from some top venture groups just a few weeks ago, and now it's formally moving ahead with an $86 million IPO.
Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.
Google Ventures' reported $100 million investment in oncology Big Data startup Flatiron Health came to fruition this week. And the deal is even bigger than early reports suggested, with Flatiron raising $130 million and buying electronic medical record business Altos Solutions.
UCLA brainchild ImaginAb has hauled in another $21 million in venture cash to advance its antibody-re-engineering technology, a biotech approach to imaging that the company believes will help personalize treatments for cancer and immune disease.
A spinoff from the Ecole Polytechnique Fédérale de Lausanne has rounded up a hefty $37.5 million A round from a prominent group of biotech investors to develop a new-and-improved portfolio of immune-tolerant therapies.
After recruiting a chief scientific officer from Epizyme, upstart cancer drug developer Loxo Oncology has nabbed a $24 million B round from some marquee venture players. New Enterprise Associates came in to lead this round, buying into the business plan of focusing on genetically-defined cancers, with existing investors Aisling Capital and OrbiMed Advisors joining in.
Evanston, IL's Naurex nailed down another $25 million in venture funding to accelerate its two-pronged depression program, posting positive midstage results for its top prospect.